Valuation: Wockhardt Limited

Market Cap 326B 3.49B 3.17B 2.93B 2.64B 4.99B 5.18B 35.3B 13.96B 176B 13.11B 12.83B 557B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 342B 3.66B 3.32B 3.07B 2.77B 5.23B 5.43B 36.98B 14.63B 185B 13.73B 13.44B 583B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.99%
Yield 2025 *
-
Yield 2026 -
1 day+1.34%
1 week+0.06%
Current month+7.09%
1 month+6.79%
3 months+9.46%
6 months+29.55%
Current year+40.77%
1 week 1,983.4
Extreme 1983.4
2,075.5
1 month 1,772
Extreme 1772
2,089
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 321
Extreme 321
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
+1.51%+0.06%+51.43%+515.42% 3.47B
-1.13%-1.17%+38.55%+139.23% 1,275B
-1.36%-0.74%+39.64%+86.06% 680B
-0.59%-0.36%+25.14%+111.73% 521B
-0.76%+1.10%+41.43%+70.96% 389B
-0.75%-3.16%+54.39%+40.90% 356B
-1.83%-0.89%+26.00%+58.48% 305B
-1.65%-0.59%+1.55%+34.52% 287B
-0.95%-1.57%+34.01%+72.55% 250B
+1.60%-0.36%+37.21%+125.66% 208B
Average -0.61%-0.46%+34.93%+125.55% 428B
Weighted average by Cap. -0.98%-0.55%+34.97%+95.96%

Financials

2025 2026
Net sales 30.35B 325M 295M 272M 246M 464M 482M 3.28B 1.3B 16.38B 1.22B 1.19B 51.74B 34.62B 371M 336M 311M 280M 529M 549M 3.74B 1.48B 18.68B 1.39B 1.36B 59.02B
Net income -470M -5.03M -4.57M -4.22M -3.81M -7.18M -7.46M -50.83M -20.11M -254M -18.87M -18.48M -801M 2.13B 22.8M 20.7M 19.12M 17.25M 32.56M 33.81M 230M 91.11M 1.15B 85.53M 83.73M 3.63B
Net Debt 14.33B 153M 139M 129M 116M 219M 227M 1.55B 613M 7.73B 575M 563M 24.43B 15.53B 166M 151M 139M 126M 237M 246M 1.68B 664M 8.38B 624M 611M 26.48B
Projected Income Statement - Annual - Wockhardt Limited
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-11-18 ₹2,039.20 +1.51% 446,999
26-11-17 ₹2,008.90 +0.22% 319,693
26-11-16 ₹2,004.50 -1.12% 561,715
26-11-13 ₹2,027.20 -1.30% 392,517
26-11-12 ₹2,054.00 +0.95% 342,889
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock